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Abstract 
 
Background: Trying to simultaneously achieve developmental milestones and cope with a life-
threatening disease may place adolescents and young adults (AYAs) at risk for impaired health-
related quality of life (HRQoL) later in life. The aim of this study was to examine differences in 
HRQoL between AYA lymphoma survivors and a normative population and to determine 
sociodemographic, clinical and long-term symptom-related factors associated with HRQoL. 
 
Material and methods: This study was part of a longitudinal, population-based survey among 
lymphoma survivors diagnosed between 1999-2012. The AYA survivor sample (18-39 years at 
time diagnosis) was compared to a sex- and age-matched normative population on HRQoL 
(EORTC QLQ-C30) and psychological distress (HADS). Multiple linear regression analyses 
were conducted to determine factors associated with HRQoL among survivors. 
 
Results: One hundred ninety-eight AYA lymphoma survivors (58%) responded to the study 
invitation. Compared to an age- and sex-matched normative population (N=380), significantly 
and clinically relevant poorer HRQoL was observed for AYA lymphoma survivors in seven 
specific domains of HRQoL: physical, role, cognitive, emotional, social functioning, fatigue and 
financial difficulties (all p< .05). In addition, AYA lymphoma survivors less often had a 
spouse/partner and more often had a lower educational level compared to the normative 
population. Linear regression analyses showed that being unemployed, female gender, having 
one or more comorbid conditions, high levels of fatigue and psychological distress were most 
strongly associated with HRQoL. 
 
Conclusions: These findings identify specific domains of life in which cancer has a significant 
and long-term impact for AYA lymphoma survivors. Future investigations are needed to identify 
and test administrations and timing of psychosocial support interventions having potential to 
reduce long-term late effects in specific HRQoL domains and promote function and adaptability 
after cancer treatment.  
 
Keywords: Adolescent and young adult cancer; lymphoma; psychological distress; (health-
related) quality of life 
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Background 
In The Netherlands, each year approximately 4,000 people are diagnosed with Non-Hodgkin 
lymphoma (NHL) and 450 with Hodgkin lymphoma (HL)[1]. Nearly 4% of the NHL and 38% of 
the HL patients are diagnosed within the adolescent and young adult (AYA) age range of 18-39 
years. Lymphoma is one of the most common cancers diagnosed at AYA age, affecting both 
males and females [2]. Advances in early cancer detection, diagnosis, and treatments have 
noticeably improved survival rates of patients with lymphoma[3]. Epidemiological data from the 
United States, however, suggest that 5-year survival rates have not improved to the same extent 
in AYAs as in children or older adults for several cancers including lymphoma[4]. Three 
potential explanations are a patient and doctors delay in diagnosis; cancers diagnosed at AYA 
age may be biologically distinct from those diagnosed at older or younger ages; and clinical trial 
participation is extremely low in this age group[5]. Although the improvement in survival of 
AYAs with cancer lags behind, the 5-year overall survival is still 95% for HL and 76% for 
NHL[4]. 
Adolescence and young adulthood is a challenging period of physical, emotional, cognitive and 
social development[6]. Important and complex age-related developmental tasks need to be 
achieved, such as forming one’s own identity and a healthy body image, establishing autonomy, 
responsibility and independence, finishing education and starting a career, getting a relationship 
and having children[6]. A cancer diagnosis may have profound effects on the lives of AYAs, 
interfering with the attainment of these normal developmental milestones. Cancer-related issues 
such as premature confrontation with mortality, changes in physical appearance, increased 
dependence on parents, disruptions of social life and school/employment because of treatment, 
and potential loss of reproductive capacity may become particularly distressing and could 
negatively impact their health-related quality of life (HRQoL) [6]. Understanding HRQoL 
outcomes among AYA lymphoma survivors is important to identify who is at risk for poor 
outcomes and to determine potential relevant services and resources required to serve them. This 
population-based study aims to (1) assess HRQoL in AYA lymphoma survivors and compare it 
to an age- and sex-matched normative population; and (2) identify sociodemographic, clinical 
and long-term symptom-related factors associated with HRQoL for this aged-defined population.  
 
4 
 
Methods 
Setting and population 
This study is part of a dynamic, longitudinal, population-based survey of lymphoma patients 
registered in the Netherlands Cancer Registry (NCR). The NCR records data on all patients who 
are newly diagnosed with cancer in the Netherlands. The NCR was used to select all survivors 
who were diagnosed with indolent (including Chronic Lymphocytic Leukemia) and aggressive 
B-cell non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL), as defined by the 
International Classification of Diseases for Oncology-3 codes (ICD-O-3), between 1/1/1999 and 
1/6/2012. Patients from 18 hospital locations and 2 large radiotherapy institutes in the southern 
part of the Netherlands, an area with 2.3 million inhabitants, were selected. Survivors who had 
cognitive impairment or were too ill at time of the study (according to advice from (former) 
treating specialist) or died prior to the start of the study (according to the NCR, hospital records, 
and the Central Bureau for Genealogy) were excluded. Ethical approval for the study was 
obtained from the local certified Medical Ethics Committee of the Maxima Medical Centre 
Veldhoven.  
For this study we only used data of patients aged 18-39 years at time of diagnosis as this is the 
AYA age range in The Netherlands. 
 
Data collection 
Data collection was done within PROFILES (Patient Reported Outcomes Following Initial 
treatment and Long term Evaluation of Survivorship). PROFILES is a registry for the study of 
the physical and psychosocial impact of cancer and its treatment from a dynamic, growing 
population-based cohort of both short and long-term cancer survivors. PROFILES contains a 
large web-based component and is linked directly to clinical data from the NCR. Details of the 
data collection method were previously described[7].  
In May 2009, patients diagnosed between January 1999 and January 2009 were included in the 
study and received the first questionnaire. In November 2009, May 2011, May 2012 and May 
2013, patients newly diagnosed up to 1/6/2012 were subsequently invited to participate. 
 
Study measures 
Health-related quality of life - EORTC-QLQ-C30 
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HRQoL was measured by the European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire (EORTC-QLQ-C30)[8]. This 30-item HRQoL questionnaire 
consists of five functional scales (physical, role, cognitive, emotional and social), a global 
quality of life scale (overall health and overall quality of life during the past week), three 
symptom scales and a number of single items assessing common symptoms and perceived 
financial impact of the disease. After linear transformation, all scales and single item measures 
range in score from 0-100. A higher score on the functional scales and global QoL means better 
functioning and HRQoL, whereas a higher score on the symptom scales means more complaints. 
Clinical important differences were determined according to the guidelines of the EORTC 
Quality of Life Group[9]. This size effect as measured by the EORTC QLQ-C30 is divided into 
four size classes: large (one representing unequivocal clinical relevance), medium (likely to be 
clinically relevant, but to a lesser extent), small (subtle but, nevertheless, clinically relevant) and 
trivial (circumstances unlikely to have any clinical relevance or where there was no difference). 
 
Psychological distress (anxiety and depression) – HADS 
Psychological distress was assessed with the Hospital Anxiety and Depression Scale (HADS), 
with seven items each for assessing symptoms of anxiety and depression [10]. All items were 
scored on a 0- to 3-point scale, with higher scores indicating more symptoms. Clinically relevant 
differences were determined according to Norman’s rule of thumb = 0.5 standard deviation[11]. 
 
Socio-demographic and clinical characteristics 
Clinical information was available from the NCR that routinely collects data on tumour 
characteristics, including date of diagnosis, tumour grade, histology, Ann Arbor stage, primary 
treatment and patients' background characteristics, including sex and date of birth. Comorbidity 
at the time of survey was categorized according to the Self-administered Comorbidity 
Questionnaire, assessing the prevalence of 14 comorbidities including heart disease, stroke, high 
blood pressure, COPD/asthma, diabetes, stomach disease, kidney disease, liver disease, anemia, 
depression, thyroid disease, osteoarthritis, back pain, and rheumatoid arthritis. Self-designed 
questions on educational level (high/intermediate/low), partnership (yes/no) and 
occupation(yes/no) were added to the questionnaire. 
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Normative population 
Normative population data was obtained from CentERpanel, an online household panel that is 
representative for the Dutch population. The process of the annual data collection, which started 
in 2009 by our study group, has been described elsewhere[12]. The data wave in 2011 included 
assessment of HRQoL. From the 2,040 (82%) respondents ≥18 years, a normative sample  
(n=380) was matched on age at time of questionnaire completion and sex. 
 
Statistical analyses 
Differences in sociodemographic and clinical characteristics between respondents and non-
respondents or survivors with unverifiable addresses, and between AYA lymphoma survivors 
and an age- and sex-matched normative population, were examined with t-tests or analysis of 
variance (ANOVA) for continuous variables and chi-square tests for categorical variables, where 
appropriate. 
The same analytical techniques were used to determine differences in HRQoL and distress 
between the AYA lymphoma survivors and an age- and sex-matched normative population. 
Hierarchical linear regression models were conducted to identify associations of demographic 
and clinical characteristics, long-term symptoms and psychological distress with HRQoL among 
AYA lymphoma survivors. The models were composed as follows: 1) demographics+clinical 
variables; 2) demographics+clinical variables+long-term symptoms (fatigue, pain, insomnia, 
financial difficulties); 3) demographics+clinical variables+psychological distress (anxiety, 
depression). All statistical tests were two-sided and considered significant if p<0.05. All analyses 
were conducted using SPSS version 22.0 (Statistical Package for Social Sciences, Chicago, IL, 
USA).  
 
Results 
 
Patient and tumor characteristics 
Of the 360 survivors selected from the NCR, 18 were excluded because of death or too ill at time 
of study. The questionnaire was completed by 198 survivors (58%). No differences were found 
between respondents, non-respondents (n=63; 18%) and survivors with unverifiable addresses 
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(n=81; 24%) with regard to age, sex, time since diagnosis, primary treatment, lymphoma type 
and disease stage (data not shown). 
AYA lymphoma survivors differed from the age- and sex-matched normative population in that 
AYA lymphoma survivors less often had a partner (p<0.01) and more often had a lower 
educational level (p<0.01) at time of questionnaire completion (n=380; Table 1).  
 
Differences in HRQoL and psychological distress between AYA lymphoma survivors and 
normative population 
AYA lymphoma survivors scored significantly worse on role, cognitive, social (all small to 
medium clinical importance), physical and emotional functioning (both trivial clinical 
importance) compared to the age- and sex-matched normative population (Figure 1). No 
significant differences were found for global quality of life.  
AYA lymphoma survivors had significantly more symptoms of fatigue and reported more 
financial difficulties (respectively of small and medium clinical importance) compared to the 
normative population (Figure 1).  
No statistically significant difference between survivors and the normative population was found 
for psychological distress. 
 
Factors associated with HRQoL of AYA lymphoma survivors 
Model 1 of the hierarchical regression analyses showed that age at cancer diagnosis was 
negatively associated with cognitive and social functioning (Table 2). Female sex was negatively 
associated with physical, role, cognitive and social functioning. Being unemployed and having 
one or more comorbid conditions were negatively associated with all scales, except social 
functioning for comorbid conditions. Explained variances ranged from 0.19 to 0.33. 
In model 2 we added fatigue which was independently, negatively associated with all functioning 
scales and global quality of life. Pain was negatively associated with physical functioning and 
global quality of life. Insomnia was negatively associated with emotional functioning and 
positively associated with social functioning, whereas financial difficulties were negatively 
associated with physical and social functioning. Explained variances ranged from 0.48 to 0.63. 
Adding anxiety in model 3 showed that anxiety was independently, negatively associated with 
physical, emotional and cognitive functioning, whereas depression was negatively associated 
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with all functioning scales and global quality of life. Explained variances ranged from 0.34 to 
0.64.  
 
Discussion 
 
In this study, AYA lymphoma survivors reported a considerably lower HRQoL compared to an 
age- and sex-matched normative population, with the largest differences for cognitive, role and 
social functioning, fatigue and financial difficulties. Our results are in line with those of two 
previously conducted studies among heterogeneous groups of AYA survivors in terms of tumor 
types[13, 14]. Data from the Adolescent and Young Adult Health Outcomes and Patient 
Experience (AYA HOPE) study, a population-based cohort of 523 AYA cancer patients 6 to 14 
months post diagnosis at study entry showed that AYA cancer survivors reported significantly 
worse HRQoL across both physical and mental scales of the Short Form-12 (SF-12) compared to 
population norms[14]. This study found the greatest deficits for AYA cancer survivors in 
limitations to physical and emotional roles, physical and social functioning and general health. A 
German study among 117 AYA cancer survivors within the first five years after diagnosis, using 
the EORTC QLQ-C30 to assess HRQoL, found that AYA cancer survivors reported poorer 
outcomes on all scales (physical, role, emotional, cognitive and social functioning) compared to 
a normative population [13]. The highest point differences were found for social, role and 
emotional functioning.   
 
Poorer functioning among AYA lymphoma survivors may mirror the cumulative effects of 
normal developmental challenges in AYAs (e.g., education, work, relationships, starting 
families) while dealing with the aftermath of cancer and its treatment. Our finding that AYA 
lymphoma survivors less often had a partner, more often a lower educational level and more 
financial problems compared to an age- and sex-matched normative population, may indicate 
that relationships, school/work and finances are negatively impacted and sustained over time by 
a diagnosis  of and treatment  for lymphoma. 
 
Although we did not find a significant difference in employment status between AYA lymphoma 
survivors and the normative population, not having a job was strongly associated with all 
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HRQoL functioning scales. It could be that reasons for unemployment are more often disease or 
disability related among AYA cancer survivors compared to controls[15]. Not having a job could 
reflect a higher severity and impact of the disease. A recent study showed that AYA cancer 
survivors who reported their cancer treatment was “very intensive” and those who had quit 
work/school after being diagnosed were more likely to report that cancer negatively affected 
their work/school after diagnosis, with more than half reporting problems with memory and 
attention[16], indicating problems with cognitive functioning. Those who remain employed 
during treatment or reenter shortly after treatment have probably less troubles to maintain 
normalcy and social reintegration with friends, peers, and others, which minimizes life disruption 
and optimizes social functioning[17]. Furthermore, a lymphoma diagnosis could significantly 
impact work plans. Not all AYA lymphoma survivors are able to get the type of job or do the 
kind of work they would have liked to do and need to adjust their goals as a result of their 
cancer, which by itself could negatively affect HRQoL. This is illustrated by a study reporting 
that AYA cancer survivors felt “left behind” in their career or job trajectories compared with 
their peers[18].  
Problems with getting back to work or finding a job after cancer may also be related to the higher 
financial difficulties experienced by AYA lymphoma survivors. In addition, there may be 
financial strains related to the cost of treatment and loss of pay resulting from time off from 
work, but AYA cancer survivors often also have lower earnings as they are in the beginning 
stages of work and vocational development. Financial independence is considered a hallmark of 
adulthood, AYA cancer survivors may need to rely on significant others for financial support, 
which can result in feelings of dependency and loss of control[18].  
Interference with work or school and financial difficulties can both result in psychological 
distress. Our finding that fewer AYA lymphoma survivors had a partner compared to the 
normative population could indicate high relationship concerns. On the one hand a negative body 
image, infertility concerns, or feelings of “abnormality” as a result of cancer and its treatment 
may lead to troubles with starting a serious relationship[19], on the other hand emotional stress 
and financial burdens of cancer can negatively impact AYA lymphoma survivors’ relationship 
with their partner. Relationship concerns by itself can lead to higher levels of psychological 
distress[19]. In our study psychological distress was strongly associated with HRQoL, however 
distress levels were not higher compared with population norms. Still our findings indicate the 
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importance of age-appropriate psychosocial support to reduce distress and help AYA lymphoma 
survivors adjust to their illness. 
 
Next to factors related to developmental milestones, age and gender were also associated with 
HRQoL. Older AYA lymphoma survivors had worse scores on cognitive and social functioning, 
which may have to do with higher work-related and social demands at time of diagnosis. Female 
gender was associated with lower HRQoL. Women in general have the tendency to report more 
problems and express emotions more easily compared to men[13]. Therefore, the association that 
we found, should not lead to the conclusion that male patients need less psychosocial support.  
Another noteworthy observation  was the lack of  differences in HRQoL between short- and 
long-term AYA lymphoma survivors. This is an interesting finding because it is an indication 
that deteriorated HRQoL scores do not improve over time. No other clinical factors (type of 
lymphoma, disease stage) were related to HRQoL. This is in congruence with the current state of 
research suggesting that subjective appraisals of cancer’s impact on one’s life may be more 
salient as contributors to HRQoL than objective cancer-related clinical factors (e.g., time since 
diagnosis, type or severity of treatment)[20]. This research suggests that survivors who report 
subjective appraisals, perceptions or experiences of how cancer has negatively affected their 
lives experience worse HRQoL[20]. Given that perceptions are malleable and change over time, 
cognitive and behavioral interventions that reframe perceptions may have the potential to 
enhance survivors’ HRQoL. On the other hand, we found that long-term symptoms such as 
fatigue were strongly associated with several functioning scales, suggesting that post-treatment 
symptom management would be helpful to diminish debilitating symptoms and improve 
functioning[14]. 
 
Despite the lower functioning scores of AYA lymphoma survivors, no difference in global 
quality of life between AYA lymphoma survivors and the normative population was found. One 
possible but not yet well investigated explanation could be that some AYA cancer survivors 
experience posttraumatic growth post-treatment[21]. It will be interesting for future research to 
identify factors that may underpin the emergence of these positive psychological outcomes to 
help development of interventions for AYA lymphoma survivors who continue to report 
symptoms psychological distress. 
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Limitations 
This study has several limitations that should be mentioned. First, the cross-sectional design 
limits the determination of changes over time in AYA lymphoma survivors’ HRQoL. 
Longitudinal studies are needed to assess within-person changes in HRQoL to identify risk 
groups for persistent lower levels of HRQoL for whom interventions are most needed. Second, 
detailed follow-up treatment and relapse data was lacking because the NCR registers only the 
primary diagnosis and treatment procedures. Third, although the CentERpanel is designed to be 
representative for the Dutch population, due to selective response on our questionnaire we have 
included a somewhat higher educated population. Fourth, we did not make use of an AYA 
cancer specific HRQoL measure, because there is a relative lack of measures developed or 
validated in this population[22]. Qualitative research highlights the need for tools measuring 
domains, such as cognition, sexual and reproductive health and social relationships[23]. An 
AYA specific HRQoL instrument in research and clinical practice will be instrumental in the 
objective evaluation of the new psychosocial and supportive care interventions that minimize or 
prevent long-term deleterious effects of cancer but also promote positive adaptation, resilience, 
and the achievement of age-specific developmental tasks. Fifth, because lymphoma is a very 
heterogeneous disease with respect to subtypes and treatment, our study can only answer the 
question how a lymphoma diagnosis at AYA age influenced HRQoL. However, the 
homogeneous study sample with respect to tumor type could also be mentioned as strength of 
this study. Compared to other studies among more heterogeneous groups of AYA cancer 
survivors, we were able to show sex differences in HRQoL not related to tumor type.  
 
Future perspectives 
Overall, our findings support  research into (early) psychosocial interventions for AYA 
lymphoma survivors  as well as the need to manage long-term symptoms, provide financial 
support and facilitate AYA lymphoma survivors’ involvement in work and/or school. Due to the 
still relatively small number of AYA survivors implementing age-appropriate interventions 
might be a challenge. Nevertheless, the recent developments of AYA-specific programs with 
multidisciplinary care teams to approach this area of need will provide new opportunities[24].  In 
addition, new media can facilitate AYA lymphoma survivors’ participation in their own care and 
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may become new modes of delivering cost-effective and easy to disseminate psychosocial 
support[25].  
 
Conclusion 
 
AYA lymphoma survivor report lower HRQoL scores compared with the normative population. 
Although overall global quality of life scores are good, impairments are experienced in the 
domains of role, cognitive and social functioning, fatigue and financial problems. Employment 
status, gender, comorbid conditions, fatigue and psychological distress were most strongly 
associated with HRQoL. Future intervention studies should explore ways to timely address poor 
functioning. 
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Table 1. Sociodemographic and clinical characteristics of AYA lymphoma patients compared to normative 
population  
 AYA cancer patients 
N=198 
N (%) 
Normative population 
N=380 
N (%) 
p-value 
Sex (Male) 112 (57%) 204 (54%) 0.47 
Age at time diagnosis – M (SD) 30.4 (6.4) NA  
Age at time diagnosis 
18-25 years 
26-39 years 
 
55 (28%) 
143 (72%) 
NA  
Age at time survey* – M (SD) 34.7 (7.4) 35.2 (8.0) 0.50 
Age at time survey* 
18-29 years 
30-35 years 
36-40 years 
≥41 years 
 
45 (23) 
59 (30) 
45 (23) 
49 (25) 
 
83 (22) 
85 (22) 
104 (27) 
108 (28) 
0.20 
Years since diagnosis – M (SD) 4.2 (2.7) NA  
Years since diagnosis 
<2 years 
2-5 years 
>5 years 
 
54 (27%) 
69 (35%) 
75 (38%) 
NA  
Tumor type 
Hodgkin Lymphoma 
Non-Hodgkin Lymphoma 
 
89 (45%) 
109 (55%) 
NA  
Stage# 
I 
II 
III 
IV 
Unknown 
 
43 (22%) 
84 (42%) 
31 (16%) 
34 (17%) 
6 (3%) 
NA  
Primary treatment  
Wait and see 
Chemotherapy alone 
Radiotherapy alone 
Stem cell transplantation 
Radiotherapy and chemotherapy 
Other therapies 
Missing 
 
15 (8%) 
85 (43%) 
9 (4%) 
1 (1%) 
82 (41%) 
5 (3%) 
1 (1%) 
NA  
Number of comorbid conditions^ – 
M (SD) 
1.3 (3.0) 0.6 (1.3) <0.01 
Number of comorbid conditions 
None 
One 
Two or more 
 
122 (62%) 
36 (18%) 
40 (20%) 
 
246 (65%) 
90 (24%) 
44 (12%) 
0.01 
Partner (yes) 137 (69%) 312 (82%) <0.01 
Job (yes) 132 (75%) 301 (79%) 0.22 
Educational level 
Low 
Middle 
High 
 
53 (27%) 
112 (58%) 
29 (15%) 
 
10 (3%) 
219 (58%) 
149 (39%) 
<0.01 
*Matching was based on age at questionnaire completion and sex 
# Disease stage was not available for some indolent Non-Hodgkin Lymphoma patients 
~22 patients had indolent Non-Hodgkin Lymphoma and 87 had aggressive Non-Hodgkin Lymphoma 
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^Comorbid conditions that were assessed included heart disease, stroke, high blood pressure, lung disease (e.g. 
COPD, asthma), diabetes, ulcer, kidney disease, liver disease, anemia, thyroid disease, depression, rheumatism, back 
pain, osteoarthritis,  
NA = not applicable 
M=mean; SD=standard deviation 
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Figure 1 Comparison of HRQoL (a), long-term symptoms (b) and psychological distress scores (c) between patients 
and normative population 
 
a 
b 
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c 
Note: *p<.05 and trivially clinically important difference; **p<.05 and small clinically important difference; *** 
p<.05 and medium clinically important difference.  
a. Scores can range from 0-100 with higher scores implying a better HRQoL. 
b. Scores can range from 0-100 with higher scores implying more symptoms 
c. Scores can range from 0-21 with higher scores implying more psychological distress 
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Table 2: Standardized betas of hierarchical multiple linear regression analyses evaluating the association of 
demographic and clinical characteristics, symptoms and psychological distress with HRQoL among AYA 
lymphoma patients 
 Global 
quality of 
life 
Beta 
Physical 
functioning 
Beta 
Role 
functioning 
 
Beta 
Emotional 
functioning 
Beta 
Cognitive 
functioning 
Beta 
Social 
functioning 
Beta 
Model 1: Demographics and clinical variables 
Age time 
diagnosis 
≥26 years (ref 
18-25 years) 
-0.09 -0.12 -0.06 -0.10 -0.21** -0.16* 
Sex 
Females (ref 
males) 
-0.04 -0.24** -0.16* -0.04 -0.21** -0.22** 
Education 
High vs. 
medium 
High vs. Low 
 
-0.06 
-0.05 
 
-0.01 
-0.03 
 
-0.12 
-0.05 
 
0.09 
0.05 
 
-0.06 
-0.02 
 
-0.08 
-0.03 
Partner 
Partner (ref no 
partner) 
-0.04 -0.01 0.04 0.13 0.03 0.11 
Job 
No (ref yes) 
-0.34** -0.35** -0.25** -0.21** -0.23** -0.16* 
Time since 
diagnosis 
-0.06 0.03 0.12 0.02 0.12 0.05 
Tumor type 
HL (ref NHL) 
0.01 -0.05 0.07 0.07 -0.02 0.07 
Stage 
1 vs. 2 
1 vs. 3 
1 vs. 4 
1 vs. missing 
 
-0.15 
-0.13 
-0.14 
-0.04 
 
0.08 
-0.08 
-0.03 
-0.03 
 
-0.05 
0.01 
-0.03 
-0.09 
 
-0.16 
-0.10 
-0.04 
-0.06 
 
-0.08 
-0.04 
-0.11 
-0.04 
 
-0.15 
-0.09 
-0.14 
0.02 
Comorbid 
conditions 
0 vs. 1 
1 vs. 2 or more 
 
-0.10 
-0.19* 
 
-0.17* 
-0.20** 
 
-0.12 
-0.21** 
 
-0.14 
-0.34** 
 
-0.18* 
-0.17* 
 
-0.14 
-0.12 
R2 0.23 0.33 0.24 0.26 0.25 0.19 
Model 2: Model 1 +  long-term symptoms 
Fatigue -0.40** -0.41** -0.66** -0.41** -0.50** -0.43 
Pain -0.25** -0.25** -0.13 -0.05 -0.01 0.01 
Insomnia -0.07 0.05 0.01 -0.28** -0.08 0.17* 
Financial 
problems 
-0.15 -0.17* -0.06 -0.08 -0.05 -0.47** 
R2 0.56 0.63 0.63 0.55 0.48 0.55 
Model 3: Model 1 + psychological distress 
Anxiety -0.15 -0.23** -0.15 -0.51** -0.31** -0.12 
Depression -0.52** -0.18* -0.30** -0.27** -0.29** -0.40** 
R2 0.50 0.45 0.36 0.64 0.47 0.34 
*p<0.05; **p<0.01 
 
